3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Polycystic Ovary Syndrome
7
Neoplasms
3
Melanoma
3
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Obesity
2
Infertility
2
Glioblastoma
2
Endometrial Neoplasms
2
Breast Neoplasms
2
Adenocarcinoma Of Esophagus
2
Uterine Cervical Neoplasms
1
TP53 Y220C Mutation
1
Sarcoma, Ewing
1
Sarcoma
1
Prostate Cancer Recurrent
1
Progression-Free Survival
1
Preleukemia
1
Posterior Fossa Ependymal Tumor
1
Osteosarcoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms by Site
1
Metabolic Diseases
1
Medulloblastoma
1
Leukoplakia, Oral
1
Leukemia, Myeloid, Acute
1
Insulin Resistance
1
Hyperandrogenism
1
Interventions
Fulvestrant
4
serabelisib
2
sapanisertib
2
ribociclib
2
palbociclib
2
tivozanib
1
pembrolizumab
1
olaparib
1
exemestane
1
abemaciclib
1
Tamoxifen
1
Secretin
1
STX-478
1
Radiotherapy
1
Pharmaceutical Preparations
1
Paclitaxel
1
Nivolumab
1
Metformin
1
Letrozole
1
Irinotecan
1
Imlunestrant
1
Gemcitabine
1
Carboplatin
1
CA-19-9 Antigen
1
Anastrozole
1
AZD1390
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Hereditary Sensory and Autonomic Neuropathies
×
Metformin
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled